Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Glaukos Corp (NY: GKOS )

83.13 USD -2.71 (-3.16%)
Official Closing Price Updated: 7:00 PM EDT, Apr 9, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Glaukos Corp

< Previous 1 2 3 4 5 6 Next >
Glaukos to Support World Glaucoma Week with Patient Education Campaign and Free Screening Initiatives
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today... 
From Business Wire News Releases
Glaukos Announces Participation in Oppenheimer Healthcare Conference
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today... 
From Business Wire News Releases
Glaukos Appoints Denice Torres and Dr. Leana Wen to its Board of Directors
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today... 
From Business Wire News Releases
Glaukos Corporation Announces Fourth Quarter and Full Year 2020 Financial Results
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today... 
From Business Wire News Releases
Glaukos Announces Positive Phase 3 Trial Results for iLink™ Epi-on Investigational Therapy That Met the Primary Efficacy Endpoint
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today... 
From Business Wire News Releases
Glaukos Corporation to Release Fourth Quarter and Full Year 2020 Financial Results after Market Close on February 25
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to... 
From Business Wire News Releases
Glaukos’ iDose® TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 24 Months in Phase 2b Study
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today... 
From Business Wire News Releases
Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2020 Net Sales
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today... 
From Business Wire News Releases
U.S. IDE Trial Results for Glaukos’ iStent infinite™ Show Substantial Reduction in IOP
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today... 
From Business Wire News Releases
Glaukos Announces Participation in J.P. Morgan Healthcare Conference
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today... 
From Business Wire News Releases
Glaukos Corporation (NYSE:GKOS) Investor Notice: Investigation over Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 11/18/2020 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Glaukos Corporation. 
From SBWire - Latest Press Releases
Glaukos Announces Participation in Upcoming Investor Conferences
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today... 
From Business Wire News Releases
Glaukos Corporation Announces Third Quarter 2020 Financial Results
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today... 
From Business Wire News Releases
Glaukos Corporation to Release Third Quarter 2020 Financial Results after Market Close on November 5
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to... 
From Business Wire News Releases
INVESTIGATION ALERT: Nationally Ranked Litigation Firm Labaton Sucharow Announces Investigation of the Merger of Avedro, Inc. and Glaukos Corporation and Strongly Encourages Investors to Contact the F
Labaton Sucharow LLP, a leading investor rights law firm, announces it is investigating potential securities claims on behalf of former shareholders of Avedro Inc. (NASDAQ: AVDR) concerning allegations... 
From Business Wire News Releases
INVESTIGATION ALERT: Nationally Ranked Litigation Firm Labaton Sucharow Announces Investigation of the Merger of Avedro, Inc. and Glaukos Corporation and Strongly Encourages Investors to Contact the F
Labaton Sucharow LLP, a leading investor rights law firm, announces it is investigating potential securities claims on behalf of former shareholders of Avedro Inc. (NASDAQ: AVDR) concerning allegations... 
From Business Wire News Releases
Glaukos Announces Participation in September Investor Conferences
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today... 
From Business Wire News Releases
Glaukos Corporation (NYSE: GKOS) Investor Notice: Investigation for Former Avedro, Inc. (Nasdaq: AVDR) Investors Announced
San Diego, CA -- (SBWIRE) -- 09/03/2020 -- An investigation for investors in formerly Avedro, Inc. (Nasdaq: AVDR), now Glaukos Corporation (NYSE: GKOS) shares over potential securities laws violations... 
From SBWire - Latest Press Releases
Glaukos Corporation (NYSE: GKOS) Investor Notice: Update in Lawsuit for Investors who held shares of Avedro, Inc. (AVDR) announced by Shareholders Foundation
From GlobeNewswire News Releases
Glaukos /Avedro (GKOS) Alert: Investigation into the Glaukos Acquisition of Avedro; Avedro Investors Receiving Glaukos Shares Encouraged to Contact Johnson Fistel
Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims against Glaukos Corporation (NYSE: GKOS) ("Glaukos" or the "Company") for violations of federal securities laws. 
From PR Newswire
Glaukos Corporation Announces Second Quarter 2020 Financial Results
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today... 
From Business Wire News Releases
Glaukos Corporation to Release Second Quarter 2020 Financial Results after Market Close on August 6
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to... 
From Business Wire News Releases
Glaukos Announces Presentation Cancellation at the William Blair 40th Annual Growth Stock Conference
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today... 
From Business Wire News Releases
Glaukos Corporation Announces Pricing of Private Offering of $250 Million of 2.75% Convertible Senior Notes
Glaukos Corporation (NYSE: GKOS) (the “Company” or “Glaukos”), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders... 
From Business Wire News Releases
Glaukos Corporation Announces Proposed Private Offering of $200 Million of Convertible Senior Notes
Glaukos Corporation (NYSE: GKOS) (the “Company” or “Glaukos”), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders... 
From Business Wire News Releases
Glaukos Announces Participation in the William Blair 40th Annual Growth Stock Conference
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today... 
From Business Wire News Releases
Glaukos Technologies Featured in Numerous Presentations at the 2020 American Society of Cataract and Refractive Surgery Virtual Annual Meeting
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced... 
From Business Wire News Releases
Glaukos Corporation Announces First Quarter 2020 Financial Results
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today... 
From Business Wire News Releases
Glaukos Corporation to Release First Quarter 2020 Financial Results after Market Close on May 7
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to... 
From Business Wire News Releases
Glaukos Provides Update on COVID-19 Impact and Preliminary Net Sales Range for the First Quarter of 2020
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today... 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.